Multimorbidity, polypharmacy, referrals, and adverse drug events: are we doing things well?

被引：152

作者：

Calderon-Larranaga, Amaia ^{[1
]}

Poblador-Plou, Beatriz ^{[1
]}

Gonzalez-Rubio, Francisca ^{[1
]}

Andres Gimeno-Feliu, Luis ^{[1
]}

Maria Abad-Diez, Jose ^{[1
]}

Prados-Torres, Alexandra ^{[1
]}

机构：

[1] Gen Hosp, Hosp Univ Miguel Servet, Zaragoza 50009, Spain

来源：

BRITISH JOURNAL OF GENERAL PRACTICE | 2012年 / 62卷 / 605期

关键词：

D O I：

10.3399/bjgp12X659295

中图分类号：

R1 [预防医学、卫生学];

学科分类号：

1004 ; 120402 ;

摘要：

Multimorbidity is associated with polypharmacy and may increase the risk of adverse drug events, which become more likely as more medical specialities are involved in management

引用

页数：2

共 48 条

[31] Stimulant medications and their adverse events and the food and drug administration: What can we conclude?
Wolraich, ML
JOURNAL OF DEVELOPMENTAL AND BEHAVIORAL PEDIATRICS, 2006, 27 (02): : 177 - 178
[32] Polypharmacy and adverse drug events among propensity score matched privately insured persons with and without spinal cord injury
Brittany N. Hand
James S. Krause
Kit N. Simpson
Spinal Cord, 2018, 56 : 591 - 597
[33] Polypharmacy and adverse drug events among propensity score matched privately insured persons with and without spinal cord injury
Hand, Brittany N.
Krause, James S.
Simpson, Kit N.
SPINAL CORD, 2018, 56 (06) : 591 - 597
[34] Risk of Adverse Drug Events Following the Virtual Addition of COVID-19 Repurposed Drugs to Drug Regimens of Frail Older Adults with Polypharmacy
Al Rihani, Sweilem B.
Smith, Matt K.
Bikmetov, Ravil
Deodhar, Malavika
Dow, Pamela
Turgeon, Jacques
Michaud, Veronique
JOURNAL OF CLINICAL MEDICINE, 2020, 9 (08) : 1 - 19
[35] Prevention of New Thromboembolic Events in Patients With Inflammatory Bowel Disease Admitted to the University Hospital: Are We Doing It Well?
Medero-Rodriguez, Priscilla M.
Torres, Esther A.
Soto-Salgado, Marievelisse
De Jesus, Charles
Mercado-Cabrera, Frantony P.
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2015, 110 : S814 - S815
[36] Management of multi-and extensively drug-resistant tuberculosis in Ukraine: how well are we doing?
Lytvynenko, N.
Cherenko, S.
Feschenko, Y.
Pogrebna, M.
Senko, Y.
Barbova, A.
Manzi, M.
Denisiuk, O.
Ramsay, A.
Zachariah, R.
PUBLIC HEALTH ACTION, 2014, 4 : S67 - S72
[37] Screening retreatment tuberculosis patients for drug resistance in mid-west Nepal: how well are we doing?
Tharu, M. B.
Harries, A. D.
Goel, S.
Srivastava, S.
Kumar, A. M. V.
Adhikari, M.
Shrestha, B.
Maharjan, B.
Khadka, H.
PUBLIC HEALTH ACTION, 2014, 4 (01): : 60 - 65
[38] The role of drug susceptibility testing in M/XDR-TB. Too little and too late - Are we doing the right things?
Hoffner, Sven Erik
INTERNATIONAL JOURNAL OF MYCOBACTERIOLOGY, 2013, 2 (04) : 191 - 193
[39] Probable effects of polypharmacy and equivalent doses of psychotropic drugs on prevalence of adverse drug events among psychiatric inpatients in a general hospital in Japan
Aoyama, Keisuke
Tachi, Tomoya
Kubo, Satoaki
Koyama, Aisa
Watanabe, Mayuko
Aoyama, Satoshi
Noguchi, Yoshihiro
Tanaka, Kazuhide
Yasuda, Masahiro
Shibata, Akihiko
Mizui, Takashi
Teramachi, Hitomi
HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL, 2024, 39 (03)
[40] Adverse drug events leading to medical emergency team activation in hospitals: what can we learn?
Harkanen, Marja
Syyrila, Tiina
Schepel, Lotta
BMJ QUALITY & SAFETY, 2023, 32 (04) : 189 - 191

← 1 2 3 4 5 →